NO20060328L - Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser - Google Patents
Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelserInfo
- Publication number
- NO20060328L NO20060328L NO20060328A NO20060328A NO20060328L NO 20060328 L NO20060328 L NO 20060328L NO 20060328 A NO20060328 A NO 20060328A NO 20060328 A NO20060328 A NO 20060328A NO 20060328 L NO20060328 L NO 20060328L
- Authority
- NO
- Norway
- Prior art keywords
- acute
- treatment
- ache inhibitor
- neurological disorders
- combination
- Prior art date
Links
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title abstract 5
- 239000005557 antagonist Substances 0.000 title abstract 5
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 title abstract 5
- 229940124596 AChE inhibitor Drugs 0.000 title abstract 4
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- 230000001154 acute effect Effects 0.000 title abstract 2
- 230000001684 chronic effect Effects 0.000 title abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03016968 | 2003-07-25 | ||
| PCT/EP2004/008020 WO2005014002A1 (en) | 2003-07-25 | 2004-07-17 | Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20060328L true NO20060328L (no) | 2006-02-17 |
Family
ID=34130033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060328A NO20060328L (no) | 2003-07-25 | 2006-01-20 | Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7235547B2 (xx) |
| EP (1) | EP1651234B1 (xx) |
| JP (1) | JP5005343B2 (xx) |
| KR (1) | KR100764330B1 (xx) |
| CN (1) | CN1856312A (xx) |
| AR (1) | AR045926A1 (xx) |
| AT (1) | ATE374030T1 (xx) |
| AU (1) | AU2004262897B9 (xx) |
| BR (1) | BRPI0412919A (xx) |
| CA (1) | CA2532347C (xx) |
| CO (1) | CO5640124A2 (xx) |
| DE (1) | DE602004009195T2 (xx) |
| DK (1) | DK1651234T3 (xx) |
| ES (1) | ES2293287T3 (xx) |
| HR (1) | HRP20070552T3 (xx) |
| IL (1) | IL173131A (xx) |
| MX (1) | MXPA06000705A (xx) |
| MY (1) | MY138394A (xx) |
| NO (1) | NO20060328L (xx) |
| NZ (1) | NZ544719A (xx) |
| PL (1) | PL1651234T3 (xx) |
| PT (1) | PT1651234E (xx) |
| RU (1) | RU2357734C2 (xx) |
| SI (1) | SI1651234T1 (xx) |
| TW (1) | TW200524614A (xx) |
| WO (1) | WO2005014002A1 (xx) |
| ZA (1) | ZA200600693B (xx) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US7488736B2 (en) * | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7576211B2 (en) * | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
| US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7598265B2 (en) * | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CA2651862A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| JP2010502722A (ja) | 2006-09-08 | 2010-01-28 | ブレインセルス，インコーポレイティド | ４−アシルアミノピリジン誘導体を含む組み合わせ |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| WO2010065743A2 (en) * | 2008-12-03 | 2010-06-10 | Nanotherapeutics, Inc. | Bicyclic compounds and methods of making and using same |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| RU2472475C2 (ru) * | 2010-04-20 | 2013-01-20 | Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) | Способ комбинированного лечения глаукомной оптической нейропатии |
| KR20150070187A (ko) | 2012-10-23 | 2015-06-24 | 에프. 호프만-라 로슈 아게 | 자폐 장애의 치료를 위한 ｍｇｌｕ２／３ 길항제 |
| KR20160143853A (ko) | 2014-04-23 | 2016-12-14 | 에프. 호프만-라 로슈 아게 | 지적 장애의 치료를 위한 mglu2/3 길항제 |
| CN112462047B (zh) * | 2020-11-13 | 2023-02-07 | 北京元恩生物技术有限公司 | 一种尼卡巴嗪检测试剂盒及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| DK1089976T3 (da) * | 1998-06-22 | 2004-01-19 | Neurosearch As | Fremgangsmåde til fremstilling af 5-bromisoquinolin og dets 8-nitroderivat |
| US6194403B1 (en) * | 1999-09-09 | 2001-02-27 | Unitech Pharmaceuticals, Inc. | Tacrine derivatives for treating Alzheimer's disease |
| PL357433A1 (en) * | 1999-10-15 | 2004-07-26 | F.Hoffmann-La Roche Ag | Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| HRP20020259A2 (en) * | 1999-10-15 | 2004-04-30 | Hoffmann La Roche | Benzodiazepine derivatives |
| CA2310926C (en) * | 2000-04-03 | 2002-10-15 | Janssen Pharmaceutica N.V. | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
| EP1203584A1 (en) | 2000-10-13 | 2002-05-08 | M.D.M. S.r.l. | Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil) |
| US6500972B2 (en) * | 2001-01-03 | 2002-12-31 | Chinese Petroleim Corp. | Synthesis of TMBQ with transition metal-containing molecular sieve as catalysts |
| US6500955B1 (en) * | 2001-02-02 | 2002-12-31 | National Institute Of Pharmaceutical Education And Research | One pot synthesis of [2,8-Bis (trifluoromethyl)-4-quinolinyl]-2-pyridinylmethanone, a mefloquine intermediate |
| EP1377640B1 (en) * | 2001-04-09 | 2017-05-17 | FUJIFILM Corporation | Azo compounds and process of producing the same and novel intermediate compounds used in the process of producing azo compounds |
| YU79103A (sh) * | 2001-04-12 | 2006-05-25 | F. Hoffmann-La Roche Ag. | Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao antagonisti mglur2 i receptora |
| IL157873A0 (en) * | 2001-04-12 | 2004-03-28 | Hoffmann La Roche | DIHYDRO-BENZO [b] [1,4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II |
| US6949542B2 (en) * | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
-
2004
- 2004-07-17 AT AT04741126T patent/ATE374030T1/de active
- 2004-07-17 WO PCT/EP2004/008020 patent/WO2005014002A1/en not_active Ceased
- 2004-07-17 CN CNA2004800278083A patent/CN1856312A/zh active Pending
- 2004-07-17 RU RU2006105721/15A patent/RU2357734C2/ru not_active IP Right Cessation
- 2004-07-17 DK DK04741126T patent/DK1651234T3/da active
- 2004-07-17 MX MXPA06000705A patent/MXPA06000705A/es active IP Right Grant
- 2004-07-17 HR HR20070552T patent/HRP20070552T3/xx unknown
- 2004-07-17 EP EP04741126A patent/EP1651234B1/en not_active Expired - Lifetime
- 2004-07-17 BR BRPI0412919-9A patent/BRPI0412919A/pt not_active Application Discontinuation
- 2004-07-17 ES ES04741126T patent/ES2293287T3/es not_active Expired - Lifetime
- 2004-07-17 AU AU2004262897A patent/AU2004262897B9/en not_active Ceased
- 2004-07-17 SI SI200430524T patent/SI1651234T1/sl unknown
- 2004-07-17 KR KR1020067001762A patent/KR100764330B1/ko not_active Expired - Fee Related
- 2004-07-17 CA CA2532347A patent/CA2532347C/en not_active Expired - Fee Related
- 2004-07-17 JP JP2006521458A patent/JP5005343B2/ja not_active Expired - Fee Related
- 2004-07-17 NZ NZ544719A patent/NZ544719A/xx unknown
- 2004-07-17 PL PL04741126T patent/PL1651234T3/pl unknown
- 2004-07-17 DE DE602004009195T patent/DE602004009195T2/de not_active Expired - Lifetime
- 2004-07-17 PT PT04741126T patent/PT1651234E/pt unknown
- 2004-07-21 TW TW093121764A patent/TW200524614A/zh unknown
- 2004-07-22 AR ARP040102592A patent/AR045926A1/es not_active Application Discontinuation
- 2004-07-22 US US10/896,494 patent/US7235547B2/en not_active Expired - Fee Related
- 2004-07-23 MY MYPI20042981A patent/MY138394A/en unknown
-
2006
- 2006-01-12 IL IL173131A patent/IL173131A/en not_active IP Right Cessation
- 2006-01-20 NO NO20060328A patent/NO20060328L/no not_active Application Discontinuation
- 2006-01-24 CO CO06006378A patent/CO5640124A2/es not_active Application Discontinuation
- 2006-01-24 ZA ZA200600693A patent/ZA200600693B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060328L (no) | Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser | |
| WO2004078116A3 (en) | P38 inhibitors and methods of use thereof | |
| BRPI0411825A (pt) | inibidores de p38 quinase a base de heterociclo de 5 elementos | |
| TW200510416A (en) | P38 inhibitors and methods of use thereof | |
| BRPI0516132A (pt) | compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica | |
| WO2006047516A3 (en) | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | |
| NO20034549L (no) | Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV | |
| CY1108725T1 (el) | Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer | |
| WO2004071431A3 (en) | Method and composition for treating neurodegenerative disorders | |
| WO2005000298A3 (en) | 5-membered heterocycle-based p-38 inhibitors | |
| ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| WO2005084654A3 (en) | Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents | |
| WO2006074265A3 (en) | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders | |
| BRPI0411864A (pt) | combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| WO2007044325A3 (en) | Apoe4 domain interaction inhibitors and methods of use thereof | |
| WO2005009340A3 (en) | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | |
| NO20073610L (no) | Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase | |
| AR020740A1 (es) | Composicion y metodo para tratar enfermedades alergicas | |
| MX2008001608A (es) | Piperazinas acetilenicas como antagonistas de receptor de glutamato metabotropico. | |
| TW200621261A (en) | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof | |
| DK1503764T3 (da) | 5-HT4-receptor-antagonister til behandling af hjertesvigt | |
| IL175358A0 (en) | 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease | |
| MXPA01009032A (es) | Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12. | |
| AR020741A1 (es) | Composicion y metodo para tratar enfermedades alergicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |